TissueTech fleshes out $10M equity round
TissueTech says it's raised $10 million in equity financing for its regenerative medicine technology.
TissueTech Inc. said it pulled down $10 million from a pair of venture capital shops to back its regenerative medicine subsidiaries, Bio-Tissue and Amniox Medical.
The equity round came from Ballast Point Ventures and River Cities Capital Funds, according to a press release.
Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (Bio-Tissue) and musculoskeletal conditions and wound care (Amniox Medical), according to the release.
The cash is earmarked for commercialization and R&D, TissueTech said.